Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
Chinese Patent Office
McKesson
US Department of Justice
Citi
Accenture
Argus Health
McKinsey

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DACLATASVIR DIHYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Daclatasvir Dihydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00546715 A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects Completed Bristol-Myers Squibb Phase 1/Phase 2 The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection
NCT00663208 A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects Completed Bristol-Myers Squibb Phase 2 The primary purpose of this study is to assess the change in Hepatitis C Virus RNA during dosing with daclatasvir and during the follow-up period in subjects with chronic hepatitis C infection
NCT00874770 Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin) Completed Bristol-Myers Squibb Phase 2 The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.
NCT01016912 Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients Completed Bristol-Myers Squibb Phase 2 The purpose of this study is to identify at least 1 dose of daclatasvir that is safe, well tolerated, and efficacious when combined with peginterferon-alfa and ribavirin for the treatment of hepatitis C virus genotype 1 in chronically infected patients who are treatment-naïve and nonresponsive to the standard of care
NCT01017575 Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin) Completed Bristol-Myers Squibb Phase 2 The purpose of this study is to identify at least 1 dose of Daclatasvir, that when combined with peginterferon-alfa (PegIFNα) and ribavirin (RBV) for the treatment of chronically infected HCV genotype 1 treatment-naïve and non-responder to standard of care subjects is safe, well tolerated, and efficacious
NCT01125189 Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients Completed Bristol-Myers Squibb Phase 2 To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than those with placebo.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Daclatasvir Dihydrochloride

Condition Name

Condition Name for Daclatasvir Dihydrochloride
Intervention Trials
Hepatitis C 46
Chronic Hepatitis C 11
Hepatitis C, Chronic 11
Hepatitis C Virus 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Daclatasvir Dihydrochloride
Intervention Trials
Hepatitis C 93
Hepatitis 68
Hepatitis A 45
Hepatitis C, Chronic 39
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Daclatasvir Dihydrochloride

Trials by Country

Trials by Country for Daclatasvir Dihydrochloride
Location Trials
United States 346
Japan 98
Canada 59
Australia 58
United Kingdom 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Daclatasvir Dihydrochloride
Location Trials
Texas 31
California 30
Florida 24
Maryland 23
Pennsylvania 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Daclatasvir Dihydrochloride

Clinical Trial Phase

Clinical Trial Phase for Daclatasvir Dihydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 31
Phase 2/Phase 3 2
[disabled in preview] 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Daclatasvir Dihydrochloride
Clinical Trial Phase Trials
Completed 62
Recruiting 17
Not yet recruiting 7
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Daclatasvir Dihydrochloride

Sponsor Name

Sponsor Name for Daclatasvir Dihydrochloride
Sponsor Trials
Bristol-Myers Squibb 60
Ain Shams University 3
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Daclatasvir Dihydrochloride
Sponsor Trials
Other 119
Industry 77
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Daiichi Sankyo
Moodys
Cerilliant
McKinsey
Teva
Healthtrust
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.